Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma
Nicola Miglino, Nora C. Toussaint, Alexander Ring, Ximena Bonilla, Marina Tusup, Benedict Gosztonyi, Tarun Mehra, Gabriele Gut, Francis Jacob, Stephane Chevrier, Kjong-Van Lehmann, Ruben Casanova, Andrea Jacobs, Sujana Sivapatham, Laura Boos, Parisa Rahimzadeh, Manuel Schuerch
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCutaneous Melanoma Detection and Management
Correction to: Nature Medicine 10.1038/s41591-025-03715-6, published online 27 May 2025.
In the version of the article initially published, the far-right column of the lower panel in Fig. 2c was missing and has now been added, as seen in Fig. 1, below. Additionally, the sentence “L.P. is a founder and shareholder of Apricot Therapeutics - a precision oncology spin-off from the University of Zurich - based on 4i drug response profiling” was missing from the Competing interests statement and has now been added. These corrections have been made to the HTML and PDF versions of the article.Fig. 1. Original and corrected Fig. 2c.